Effect of Pseudomonas aeruginosa exotoxin A on CD3-induced human T-cell activation. 1998

J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
Department of Immunology, Child Health Center, Warsaw, Poland.

The effect of Pseudomonas aeruginosa (PA) exotoxin A (P-ExA) on CD3-induced T-cell activation was studied on the level of T-cells (proliferation, synthesis of interleukin (IL)-2, expression of IL-2R complex, ICAM-1,2 and LFA-1 molecules), and on the level of monocytes (expression of ICAM-1,2, LFA-1 molecules, as well as FcRI and CD14 receptors). We found that: (1) P-ExA blocked T-cell proliferation and this effect was totally reversed by intact monocytes, and partially by IL-2 or TPA but not by costimulatory cytokines (IL-1alpha, IL-1beta, TNF-alpha or IL-6); (2) P-ExA transiently, in short-term cultures (48 h), inhibited synthesis of IL-2; (3) prolonged stimulation (96 h) of peripheral blood mononuclear cells (PBMC) or CD4 + T-cells with P-ExA in high or low doses (100 and 10 ng/ml, respectively), enhanced the level of IL-2 in the cultures; (4) P-ExA at low dose, combined with IL-1beta, TNF-alpha or IL-6, up-regulated synthesis of IL-2; and (5) stimulation of T-cells with anti-CD3 monoclonal antibody (mAb) and P-ExA at high dose diminished the expression of the p55 chain but not of the p75 chain of IL-2R complex and slightly affected the expression of CD3 complex, ICAM-1,2 and LFA-1 molecules. Hence, P-ExA can regulate the level of IL-2 in cultures of CD3-induced T-cells either by inhibition of IL-2 consumption (when P-ExA is applied in high dose), or by induction of IL-2 production (a costimulatory effect exerted by P-ExA in low dose in combination with monokines). Action of P-ExA on monocytes resulted in: (1) inhibition of the expression of ICAM-1,2 molecules and their ligand LFA-1 molecule; (2) low expression of FcRI receptor (a ligand for Fc part of CD3 mAb); and (3) inhibition (over 90%) of the expression of CD14 molecule. In conclusion, P-ExA-induced anergy of T-cells depends on: (a) decrease in the affinity of IL-2R complex on activated T-cells; and (b) inhibition of the accessory activities of monocytes.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005098 Exotoxins Toxins produced, especially by bacterial or fungal cells, and released into the culture medium or environment. Exotoxin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000097668 Pseudomonas aeruginosa Exotoxin A An NAD-dependent ADP-ribosyltransferase that catalyzes the transfer of the ADP ribosyl moiety of oxidized NAD onto elongation factor 2 (EF-2) thus arresting protein synthesis. Commonly used as the toxin in immunotoxins. Exotoxin A, Pseudomonas,Exotoxin A, Pseudomonas aeruginosa,Recombinant Truncated Pseudomonas Exotoxin A, Form PE38QQR,Recombinant Truncated Pseudomonas Exotoxin A, Form PE40,ToxA protein, Pseudomonas aeruginosa,ETA, Pseudomonas,PE38QQR,PE40 toxin
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
June 1972, The Journal of infectious diseases,
J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
January 1989, Archivum immunologiae et therapiae experimentalis,
J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
January 1992, Targeted diagnosis and therapy,
J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
June 1980, The New England journal of medicine,
J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
January 1997, Acta oto-laryngologica,
J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
October 1982, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
September 1990, Journal of clinical immunology,
J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
July 1972, The Journal of infectious diseases,
J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
March 2000, Acta oto-laryngologica,
J Michalkiewicz, and J Stachowski, and C Barth, and J Patzer, and D Dzierzanowska, and D Runowski, and K Madalinski
January 1993, Toxicon : official journal of the International Society on Toxinology,
Copied contents to your clipboard!